Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton, JW; Menzies, NA; Stover, J; Cambiano, V; Chindelevitch, L; Cori, A; Hontelez, JA; Humair, S; Kerr, CC; Klein, DJ; +42 more... Mishra, S; Mitchell, KM; Nichols, BE; Vickerman, P; Bakker, R; Bärnighausen, T; Bershteyn, A; Bloom, DE; Boily, MC; Chang, ST; Cohen, T; Dodd, PJ; Fraser, C; Gopalappa, C; Lundgren, J; Martin, NK; Mikkelsen, E; Mountain, E; Pham, QD; Pickles, M; Phillips, A; Platt, L; Pretorius, C; Prudden, HJ; Salomon, JA; van de Vijver, DA; de Vlas, SJ; Wagner, BG; White, RG; Wilson, DP; Zhang, L; Blandford, J; Meyer-Rath, G; Remme, M; Revill, P; Sangrujee, N; Terris-Prestholt, F; Doherty, M; Shaffer, N; Easterbrook, PJ; Hirnschall, G; Hallett, TB; (2013) Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global health, 2 (1). pp. 23-34. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(13)70172-4

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2214-109X(13)70172-4

Abstract

Share

Download

Filename: Health benefits, costs, and cost-effectiveness_GOLD VoR.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar